Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2485246 | 0.76 | — | — | |
| SCHEMBL3557928 | 0.67 | — | — | |
| SCHEMBL8078733 | 0.67 | SMN1; SMN2 (0.50) | SMN1; SMN2CA1CA9 | |
| SCHEMBL8078738 | 0.67 | SMN1; SMN2 (0.50) | SMN1; SMN2CA1CA9 | |
| SCHEMBL2559278 | 0.65 | — | — | |
| SCHEMBL17658862 | 0.63 | NISCH (0.49) | SMN1; SMN2 | |
| SCHEMBL13201161 | 0.62 | — | — | |
| SCHEMBL6311458 | 0.62 | — | — | |
| SCHEMBL13201155 | 0.62 | — | — | |
| SCHEMBL10623492 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340532-B2 | Methods and compositions for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340532-B2 | Methods and compositions for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | CNKSR1, CAMKK1, CAMKK2 | SMN1; SMN2 3206/4885CA1 3061/4885CA9 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.